ClinicalTrials.gg
Active, not recruitingNCT06116916Updated Oct 14, 2026

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

A Phase 2 interventional study of KHK4951 and Aflibercept Injection in Diabetic Macular Edema (DME), sponsored by Kyowa Kirin Co., Ltd.. Active, not recruiting at 87 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
63rd of 244
185 · median 45
Started
2024
with 8 others
Phase 2
63 of 276
3 open now
Primary completion
2026-10
later than 8 of 31 live
Registered
250th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 63rd largest by enrollment of the 244 interventional ones that give a count, is one of 9 that started in 2024, is one of 63 in phase 2, reaches primary completion later than 8 of the 31 other live ones, and was the 250th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

03

Conditions studied

  • Diabetic Macular Edema (DME)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written to participate in the study
  • In Korea, participants must be 19 years or older to be enrolled
  • BCVA ETDRS letter score of 78 letters to 35 letters as measured by the ETDRS visual acuity chart in the study eye at screening
  • 500 μm ≥ CST ≥ 325 μm in the study eye at screening
  • ≤ 11% at screening

Exclusion criteria

Exclusion Criteria:

  • Any signs of proliferative diabetic retinopathy in the study eye
  • History of rubeosis in the study eye
  • Uncontrolled glaucoma in the study eye
  • Aphakia or pseudophakia with AC-IOL in the study eye
  • Active intraocular inflammation in the study eye
  • Any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye
  • History of rhegmatogenous retinal detachment in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • History of the following therapies in the study eye

    • History of vitrectomy surgery, submacular surgery, or other surgical intervention for DME
    • Periocular or intraocular (sub-Tenon or IVT) within 12 weeks prior to Day 1 corticosteroids
    • Previous intraocular device implantation except PC-IOL
    • Laser (any type) to the macular area within 12 weeks prior to Day 1
    • Peripheral retinal photocoagulation therapy within 12 weeks prior to Day 1
    • Previous treatment with IVT anti-VEGF drugs other than ranibizumab, bevacizumab, aflibercept 2 mg, and their biosimilars
    • Treatment with ranibizumab, bevacizumab, aflibercept 2 mg, or their biosimilars within 12 weeks prior to Day 1. Previously treated patients who received these medications more than 12 weeks prior to Day 1 can be enrolled, but the patients should be diagnosed with DME within 3 years prior to Day 1
    • Previous use of Ozurdex® or Iluvien® implant
  • Any current or history of endophthalmitis in either eye
  • History of idiopathic or -associated uveitis in either eye
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    Arm A

    KHK4951 High dose

    Drug: KHK4951 · Drug: Aflibercept Injection

  • Experimental
    Arm B

    KHK4951 Middle dose

    Drug: KHK4951 · Drug: Aflibercept Injection

  • Experimental
    Arm C

    KHK4951 Low dose

    Drug: KHK4951 · Drug: Aflibercept Injection

Interventions

  • KHK4951 eye drop for 36 weeks until end of the trial

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

06

What researchers measure

Primary outcomes

  1. Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline

    Time frame: For 36 weeks until the end of the trial

Secondary outcomes

  1. The number of aflibercept IVT

    Time frame: For 36 weeks until the end of the trial

  2. Change from baseline in SHRM as measured by SD-OCT

    Time frame: 36 Weeks

  3. Change from baseline in retinal morphology as measured by SD-OCT

    Time frame: 36 Weeks

  4. Change from baseline in leakage as measured by FA

    Time frame: 36 Weeks

Other outcomes

  1. Number of participants with adverse events

    Time frame: For 36 weeks until the end of the trial

  2. Serum KHK4951 concentration

    Time frame: 36 Weeks

07

Study locations

87 sites
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowakirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Oct 2026, 33 months after the start.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 33 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Aug 2026 → Oct 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 3, 2023
StartActual
Jan 9, 2024
Primary completionEst.
Oct 31, 2026was Aug 2026
CompletionEst.
Nov 30, 2026was Sep 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Oct 31, 2026
Oct 14, 2026
Study completion
Sep 30, 2026→Nov 30, 2026
Oct 14, 2026
Enrollment
150 (estimated)→185 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Aug 31, 2026→Oct 31, 2026
    Study completion Sep 30, 2026→Nov 30, 2026
    Enrollment 150 (estimated)→185 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06116916
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Jan 9, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 14, 2026

Study contacts

Sotaro Takigawa
study director · Kyowa Kirin Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KHK4951

Start the discussion